Short answer
TransMedics Group, Inc. (TMDX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $203M (up 41.1% year over year) with net income of $17M.
Q3 2026 key financials · XBRL
- Revenue
- $203M
- +41.1% YoY · +6.9% QoQ
- Net income
- $17M
- −29.8% YoY · +16.3% QoQ
- Operating margin
- 13.9%
- Gross margin
- 58.5%
- EPS (diluted)
- $0.47
- −28.8% YoY · +14.6% QoQ
Source: XBRL data from the TransMedics Group, Inc. (TMDX) Q3 2026 10-Q on SEC EDGAR. USD.
TransMedics Group, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $203.0M, up $59.2M YoY from $143.8M
- Gross margin 58% vs 59% YoY, product margin 79% vs 79%
- OCS Liver strongest, $150.2M vs $107.9M; OCS Lung weakest, $3.1M vs $3.7M
- Cash $493.0M; nine-month operating cash flow $77.8M vs $158.3M
- Outlook: revenue growth from NOP and international expansion, with tariff, supply-chain and reimbursement risks
Risk Factors
- No material changes to risk factors since the 2025 Form 10-K
- Carried-forward business risks remain detailed in the 2025 Form 10-K
- No new regulatory, legal, operational, market, or financial risks identified
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TransMedics Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.